"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
| Descriptor ID |
D020123
|
| MeSH Number(s) |
D02.540.505.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 2 | 2 | 4 |
| 2001 | 2 | 2 | 4 |
| 2002 | 2 | 2 | 4 |
| 2003 | 5 | 5 | 10 |
| 2004 | 8 | 10 | 18 |
| 2005 | 14 | 4 | 18 |
| 2006 | 13 | 3 | 16 |
| 2007 | 12 | 4 | 16 |
| 2008 | 7 | 16 | 23 |
| 2009 | 16 | 11 | 27 |
| 2010 | 12 | 19 | 31 |
| 2011 | 18 | 10 | 28 |
| 2012 | 12 | 16 | 28 |
| 2013 | 16 | 15 | 31 |
| 2014 | 22 | 14 | 36 |
| 2015 | 12 | 15 | 27 |
| 2016 | 5 | 8 | 13 |
| 2017 | 3 | 9 | 12 |
| 2018 | 4 | 6 | 10 |
| 2019 | 5 | 3 | 8 |
| 2020 | 3 | 4 | 7 |
| 2021 | 4 | 3 | 7 |
| 2022 | 1 | 9 | 10 |
| 2023 | 0 | 4 | 4 |
| 2024 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Lancet Oncol. 2024 Jul; 25(7):912-921.
-
Controlled Delivery of Rosuvastatin or Rapamycin through Electrospun Bismuth Nanoparticle-Infused Perivascular Wraps Promotes Arteriovenous Fistula Maturation. ACS Appl Mater Interfaces. 2024 Jul 03; 16(26):33159-33168.
-
Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update. J Clin Oncol. 2024 May 01; 42(13):1472-1476.
-
Sirolimus for vascular anomalies in the first year of life: a systematic review. J Perinatol. 2024 Aug; 44(8):1087-1097.
-
TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis Complex. Nat Commun. 2024 Jan 09; 15(1):406.
-
Mammalian target of rapamycin inhibitors: A new-possible approach for in-utero medication therapy. Prenat Diagn. 2024 01; 44(1):88-98.
-
mTORC1 regulates the metabolic switch of postnatal cardiomyocytes during regeneration. J Mol Cell Cardiol. 2024 02; 187:15-25.
-
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. ESMO Open. 2023 Dec; 8(6):101609.
-
Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial. JCI Insight. 2023 04 24; 8(8).
-
Bioresorbable stents: We have more work to do. Catheter Cardiovasc Interv. 2023 05; 101(6):978-979.